F
Femtobiomed
Multiplexed cell engineering solutions for decentralized cell therapy manufacturing
About Femtobiomed
Femtobiomed operates in the biotechnology sector, focusing on providing advanced solutions for cell therapy manufacturing. The company specializes in multiplexed cell engineering, utilizing partitioned flow transfection technology to enhance targeted gene delivery. This approach aims to empower researchers and clinicians by unlocking new possibilities in cell therapy, ultimately shaping the future of healthcare. Femtobiomed's business model revolves around offering cutting-edge devices and support to facilitate decentralized cell therapy manufacturing, catering primarily to researchers and clinicians in the healthcare industry. The company generates revenue through the sale of its specialized devices and associated services, positioning itself as a key player in the cell therapeutics market.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Dec 2022 | $16M | $65M | Yukyung PSG Asset Management | ↗ |
| OtherOther financing | Jan 2015 | $0 | — | ActnerLab | ↗ |
Growth signals
Latest recorded traffic for Femtobiomed is 1.4K monthly website visits, up 7.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Femtobiomed in the Seongnam-si ecosystem
The Femtobiomed office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- YMYukyung PSG Asset Management
Other known investors3 additional known investors
ActnerLab- APABC partners
Korea Investment Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Femtobiomed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Femtobiomed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










